Announcements
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
More ▼
Key statistics
On Friday, ProQR Therapeutics NV (0PQ:BER) closed at 1.82, -29.21% below its 52-week high of 2.56, set on Jan 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.82 |
---|---|
High | 1.82 |
Low | 1.82 |
Bid | 1.80 |
Offer | 1.84 |
Previous close | 1.82 |
Average volume | 160.00 |
---|---|
Shares outstanding | 81.35m |
Free float | 63.11m |
P/E (TTM) | -- |
Market cap | 159.46m USD |
EPS (TTM) | -0.3725 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:04 BST.
More ▼